Gossamer Bio regains Nasdaq compliance with bid price

SAN DIEGO, CA – Gossamer Bio, Inc. (GOSS), a pharmaceutical company based in San Diego, announced today that it has regained compliance with the Nasdaq’s minimum bid price requirement, closing the matter regarding its continued listing on the Nasdaq Global Select Market. The company’s stock, currently trading at $1.42, has shown remarkable momentum with a 47.86% gain over the past six months.

The company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that it has satisfied the minimum bid price condition outlined in Nasdaq Listing Rule 5450(a)(1). This development follows a previous communication from Nasdaq on September 11, 2024, which indicated that Gossamer Bio’s common stock had not maintained the required minimum bid price of $1.00 or more for 30 consecutive business days. InvestingPro analysis shows the stock has maintained strong momentum, with an 8.66% gain in the past week alone.

Gossamer Bio’s stock, trading under the ticker (NASDAQ:GOSS), had been under scrutiny for failing to meet the bid price criterion, a key requirement for continued listing on the exchange. The receipt of this letter marks the resolution of the issue and signifies that the company’s stock price has been consistently at or above the $1.00 threshold necessary to meet Nasdaq’s standards.

The compliance achievement is a positive step for Gossamer Bio, ensuring its continued presence on a major stock exchange, which can be crucial for investor confidence and the ability to raise capital. The company, with a market capitalization of $322.91 million, maintains a strong financial position with more cash than debt on its balance sheet and liquid assets exceeding short-term obligations. The company specializes in the development of pharmaceutical preparations and operates under the organization name 03 Life Sciences. According to InvestingPro analysis, while the stock appears overvalued at current levels, five analysts have recently revised their earnings expectations upward for the upcoming period.

This announcement was made in accordance with the SEC filing requirements and provides assurance to shareholders and potential investors regarding the company’s stock market standing. Gossamer Bio, Inc., incorporated in Delaware with a fiscal year ending on December 31, remains focused on advancing its operations and product development within the pharmaceutical industry.

The information in this article is based on a press release statement from Gossamer Bio, Inc. and reflects the latest developments regarding the company’s compliance with Nasdaq listing requirements.

In other recent news, Gossamer Bio presented new research findings on its drug candidate seralutinib at the Pulmonary Vascular Research Institute 2025 Annual Congress in Rio de Janeiro, Brazil. The studies highlighted the potential benefits of seralutinib in treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The research included preclinical models and post-hoc analysis from the TORREY open-label extension study, which suggested sustained benefits of seralutinib treatment. Gossamer Bio continues to focus on addressing the unmet medical needs of patients with pulmonary hypertension through its ongoing investigation of seralutinib’s efficacy and safety.

In related developments, investment bank Piper Sandler highlighted Gossamer Bio among six stocks with de-risked Phase 3 readouts or interim analyses expected in 2025. Piper Sandler’s report provided insights into the study designs, expected timing, and success criteria for these trials. This follows a review of third-quarter 2024 earnings and year-end 2024 data, indicating potential catalysts for biotechnology companies into 2025. The report also identified other companies expected to present significant data catalysts within the next 12 months. Piper Sandler’s analysis underscores the potential impact of these developments on the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.